Englander Institute for Precision Medicine

Publications

Found 5 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Clinical Trials, Phase II as Topic  [Clear All Filters]
2023
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.
2021
Vitale I, Yamazaki T, Wennerberg E, Sveinbjørnsson B, Rekdal Ø, Demaria S, Galluzzi L.  2021.  Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.. Trends Cancer. 7(6):557-572.
2020
Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST.  2020.  An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.. Expert Opin Pharmacother. 21(8):863-870.
Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillessen SSilke, Sternberg CN, Berruti A, De Braud FGuglielmo et al..  2020.  Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.. Cancer Treat Rev. 88:102057.
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E et al..  2020.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration.. J Clin Oncol. 38(32):3763-3772.